Lundbeck's Experimental Drug Reduces Migraine Days in Trial

• Bocunebart targets the PACAP pathway, distinct from CGRP targeted by existing migraine drugs, potentially offering an alternative for patients unresponsive to current therapies
• In the intravenous trial, the drug reduced monthly migraine days by 4.24 days versus 2.86 for placebo (1.38-day placebo-adjusted reduction) in patients with one to four prior treatment failures
• Pooled data in severe, chronic migraine patients showed a stronger effect of 2.31 additional days reduction versus placebo, with the drug generally well tolerated and no new safety concerns

Lundbeck's Experimental Migraine Drug Shows Positive Mid-Stage Trial Results

Key Findings:

Denmark's Lundbeck reported positive mid-stage trial results for bocunebart, an experimental migraine treatment targeting a novel pathway. The intravenous drug reduced monthly migraine days by an average of 4.24 days versus 2.86 days for placebo over weeks 1-12 in patients who had failed one to four prior preventive treatments—a placebo-adjusted reduction of 1.38 days.

Clinical Significance:

Bocunebart targets the PACAP pathway, distinct from the CGRP pathway used by existing migraine preventatives. This offers a potential alternative for patients unresponsive to current therapies. In pooled data for severe, chronic migraine patients, the drug demonstrated stronger efficacy with a 2.31-day placebo-adjusted reduction in monthly migraine days.

Safety Profile:

The drug was generally well tolerated with no new safety concerns. The most common adverse event, affecting at least 5% of patients, was nasopharyngitis (cold-like symptoms).

Market Context:

The results were presented at the American Headache Society congress in Orlando, Florida on June 4. Jefferies analysts had anticipated modest improvement from a prior single-dose study that showed a two-day placebo-adjusted reduction over four weeks. The investment bank forecasts peak global sales of $400 million for bocunebart.

Implications:

These results support further development of a new treatment class for migraine, one of the world's most common neurological disorders, potentially expanding options for treatment-resistant patients in a significant therapeutic market.